Quizartinib is a FLT3 inhibitor used in combination with cytarabine and anthracycline to treat acute myeloid leukemia with FLT3 internal tandem duplication. Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in...
- Mechanism
- Curator reviewed · 1 reference
Quizartinib is a small molecule inhibitor of the receptor tyrosine kinase FLT3. Quizartinib and its major active metabolite AC886 bind to the adenosine triphosphate (ATP) binding domain of FLT3 with comparable affinity, and both had 10-fold lower affinity towards FLT3-ITD mutation compared to FLT3 in a binding assay. Quizartinib and AC886 inhibited FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation.
- Primary indication
- Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that...Curator reviewed · 2 structured indications
- Formula / weight
- C29H32N6O4S · 560.67 g/mol (avg)
- First approval
- Canada, 2025 · United States, 2023
- Code names
- AC-010220 · AC-220
- Brand names
Resolves to
CVWXJKQAOSCOAB-UHFFFAOYSA-NSMILESCC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1What you can answer from here — as of September 23, 2026
Which drugs share a target with Quizartinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account